Genomes and Genes


Joseph A Nicolazzo


Affiliation: Monash University
Country: Australia


  1. Pan Y, Omori K, Ali I, Tachikawa M, Terasaki T, Brouwer K, et al. Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease. J Pharm Sci. 2019;: pubmed publisher
    ..These changes could affect the interpretation of studies conducted during drug development using this mouse model of AD and potentially impact dosage regimens of such drugs prescribed in this patient population. ..
  2. McInerney M, Pan Y, Volitakis I, Bush A, Short J, Nicolazzo J. The Effects of Clioquinol on P-glycoprotein Expression and Biometal Distribution in the Mouse Brain Microvasculature. J Pharm Sci. 2019;: pubmed publisher
    ..This study has shown that under this dosing regimen, CQ does not increase BBB P-gp expression in Swiss outbred mice, but that CQ facilitates redistribution of certain metal ions within the brain MEF, plasma, and brain parenchyma. ..
  3. Lee G, Kappler K, Porter C, Scanlon M, Nicolazzo J. Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner. Pharm Res. 2015;32:3432-46 pubmed publisher
    ..hFABP3, 4 and 5 are expressed at the human BBB and bind differentially to a diverse range of lipophilic drugs. The unique expression and binding patterns of hFABPs at the BBB may therefore influence drug disposition into the brain. ..
  4. request reprint
    Pan Y, Khalil H, Nicolazzo J. The Impact of Docosahexaenoic Acid on Alzheimer's Disease: Is There a Role of the Blood-Brain Barrier?. Curr Clin Pharmacol. 2015;10:222-41 pubmed
  5. Pan Y, Short J, Newman S, Choy K, Tiwari D, Yap C, et al. Cognitive benefits of lithium chloride in APP/PS1 mice are associated with enhanced brain clearance of β-amyloid. Brain Behav Immun. 2018;70:36-47 pubmed publisher
  6. Pan Y, Nicolazzo J. Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. Adv Drug Deliv Rev. 2018;135:62-74 pubmed publisher
  7. Jin L, Boyd B, White P, Pennington M, Norton R, Nicolazzo J. Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. J Control Release. 2015;199:37-44 pubmed publisher
    ..This study demonstrated that the buccal mucosa is a promising administration route for the systemic delivery of ShK for the treatment of autoimmune diseases. ..
  8. Jin L, Zhou Q, Chan H, Larson I, Pennington M, Morales R, et al. Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases. J Pharm Sci. 2016;105:650-656 pubmed publisher
    ..2 ± 5.2% and 44.5 ± 12.5%, respectively. This study demonstrated that pulmonary administration is a promising alternative for systemically delivering HsTX1[R14A] for treating autoimmune diseases. ..
  9. Marxen E, Jin L, Jacobsen J, Janfelt C, Hyrup B, Nicolazzo J. Effect of Permeation Enhancers on the Buccal Permeability of Nicotine: Ex vivo Transport Studies Complemented by MALDI MS Imaging. Pharm Res. 2018;35:70 pubmed publisher
    ..MALDI MSI was shown to complement ex vivo permeability studies and to be a useful qualitative tool for visualizing drug and penetration enhancer distribution in buccal mucosa. ..

More Information


  1. McInerney M, Roberts K, Thompson P, Li J, Nation R, Velkov T, et al. Quantitation of Polymyxin-Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe. J Pharm Sci. 2016;105:1006-1010 pubmed publisher
  2. McInerney M, Volitakis I, Bush A, Banks W, Short J, Nicolazzo J. Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells. Pharm Res. 2018;35:83 pubmed publisher
    ..6-fold). Enhanced delivery of copper to human brain microvascular endothelial cells is associated with enhanced expression and function of the important efflux pump P-gp, which may provide therapeutic opportunities for P-gp modulation. ..
  3. McInerney M, Pan Y, Short J, Nicolazzo J. Development and Validation of an In-Cell Western for Quantifying P-Glycoprotein Expression in Human Brain Microvascular Endothelial (hCMEC/D3) Cells. J Pharm Sci. 2017;106:2614-2624 pubmed publisher
    ..The correlation of P-gp upregulation by WB, rhodamine-123 uptake, and the ICW protocol provide validation of a new ICW method as an alternative method for quantification of P-gp in hCMEC/D3 cells. ..
  4. Lee G, Pan Y, Scanlon M, Porter C, Nicolazzo J. Fatty Acid-Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells. J Pharm Sci. 2018;107:1185-1193 pubmed publisher
    ..Therefore, although FABP5 facilitates brain endothelial cell uptake of fatty acids, it has limited effects on brain endothelial cell uptake and BBB transport of drugs with lower affinity for FABP5. ..
  5. Jin L, Boyd B, Larson I, Pennington M, Norton R, Nicolazzo J. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa. J Pharm Sci. 2016;105:2173-9 pubmed publisher
    ..9 ± 9.7 and 31.0 ± 2.3 nM·h, respectively. The buccal mucosa is a promising alternative administration route for the systemic delivery of HsTX1[R14A] for the treatment of autoimmune diseases. ..
  6. request reprint
    Pan Y, Short J, Choy K, Zeng A, Marriott P, Owada Y, et al. Fatty Acid-Binding Protein 5 at the Blood-Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function. J Neurosci. 2016;36:11755-11767 pubmed
    ..g., Alzheimer's disease), may provide a novel therapeutic approach for restoring cognitive function. ..
  7. Newman S, Pan Y, Short J, Nicolazzo J. Assessing the Impact of Lithium Chloride on the Expression of P-Glycoprotein at the Blood-Brain Barrier. J Pharm Sci. 2017;106:2625-2631 pubmed publisher
  8. McInerney M, Short J, Nicolazzo J. Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access. AAPS J. 2017;19:940-956 pubmed publisher
    ..Lastly, we include within this review research that focuses on how altered properties of the BBB in AD impact upon CNS exposure of therapeutic agents and the potential clinical impact that this may have on people with this disease. ..